FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies The FDA didn't bring peptides back. It opened a formal docket. And that distinction matters. This is not a blanket approval. Not a wellness free for all. Not one announcement that changes everything overnight. Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law : ? The FDA just removed 12 peptides (BPC157, TB500, Epitalon, GHKCu inj., DSIP, MOTSc, Semax, PEGMGF, Melanotan II, LL37, Dihexa, KPV) from Category 2 (donotcompound FDA Removes BPC 157, TB 500 and 10 More Peptides from Category 2 (April 2026) You may have seen headlines recently claiming peptides like MOTS C or BPC 157 are back let's talk about what this means. In 2023, the FDA placed 19 commonly used peptides into Category